New drug combo shows promise in shrinking advanced kidney tumors before surgery
NCT ID NCT04393350
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with locally advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the combination for 12 weeks before their operation. The goal is to see how many patients experience tumor shrinkage and to monitor side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Could an ALS drug clear the fog of chemo brain?
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return